Introduction
============

Brucellosis remains a main source of disease in humans and animal husbandry worldwide ([@B11]).- About half a million human brucellosis cases are reported annually. However according to the [@B25] estimates, the true frequency of the disease is 10--25-times higher than the reported number. The highest annual incidence rates are reported from the Middle Eastern countries, such as Syria, Iraq, Iran, and Saudi Arabia ([@B20]). In Iran, where Brucellosis is endemic, the incidence of the disease is up to 34 per 100,000 per year in certain areas ([@B18]).

Brucellosis is caused by several species of Gram-negative facultative intracellular bacteria of the genus *Brucella* that can be transmitted to humans by direct animal contact or their products; it is an occupational hazard to those involved in certain professions including farmers, veterinarians, and laboratory and slaughterhouse workers ([@B24]). As a consequence of, there is severe human suffering from the disease, which may cause enormous economic losses in endemic regions.

The clinical picture of brucellosis is so strange and protean that it can be easily bewildered with other infectious and noninfectious diseases, leading to diagnostic delays and late onset of therapy ([@B03]). Therefore, laboratory confirmation is needed for detection of *Brucella*. However, there is no completely reliable and satisfactory diagnostic procedure for brucellosis ([@B07]).

There are currently three major approaches for the diagnosis of brucellosis including microbiological, serological, and molecular techniques ([@B04]). The diagnostic standard remains the isolation of *Brucella* from blood cultures or host tissues ([@B21]). The accuracy of blood cultures is reaching 70--80% of cases in acute forms produced by *Brucella melitensis*. However, in cases of chronic forms and in patients with focal complications and also infections caused by *Brucella abortus* and *Brucella suis*, culture positive results rarely exceed 30--50% ([@B27]). Furthermore, blood culture is a time-consuming and represents a potential hazard of infection for lab personnel as *Brucella* species are class III pathogens ([@B08]). In the absence of adequate culture facilitates the diagnosis of brucellosis depends on serological tests ([@B04]), such as the Rose Bengal test, serum agglutination test, Coombs test, and immune capture test, but the specificity of these techniques are low in endemic areas, in persons exposed professionally to *Brucella* or in patients with relapse or a recent history of brucellosis ([@B09]). Cross-reactivity may occur with other Gram negative bacteria that can affect the specificity. There are also some restrictions in the detection of causative agent in early phases of the disease ([@B26]; [@B05]). Alternatively, molecular techniques could be used for diagnosis of human brucellosis, especially that these kinds of procedures are useful for diagnosis of several infectious diseases caused by fastidious or slowly growing bacteria and also have detected the small amounts of DNA in different samples ([@B23]; [@B03]).

The main aim of this project was to investigate the utility of PCR for the diagnosis of brucellosis and determination of *brucella* species from the serum samples of high risk individuals, and to compare the PCR protocol's sensitivity with the conventional standard tube agglutination diagnostic method.

Materials and Methods
=====================

Subjects and serum samples
--------------------------

A total of 160 serum samples were collected from high risk individuals to brucellosis referred to "Danesh" private diagnostic laboratory in Khodabandeh district and also two governmental diagnostic laboratories in Zanjan, Iran, over a period of 8 month (January--September 2011).

All patients had clinical signs similar to brucellosis. The diagnosis was performed using serologic techniques: serum samples were analyzed before starting an antibiotic treatment by the standard tube agglutination test (STA) and also complementary tests including 2-ME (2- Mercaptoethanol) and Coombs test were investigated for further confirmation.

In the current study, a positive STA titer was defined as either equal or greater than 1:160, and the Coombs' Wright was considered as either equal or greater than 1:80, according to the standard methods ([@B10]). Samples based on Wright data in the laboratory record forms were further divided into three subgroups (Wright \> 1:160, Wright \> 1:160, and Wright Negative).

Isolation of DNA from clinical serum samples
--------------------------------------------

DNA was isolated from serum samples (100 μL) with the High yield DNA Purification kit (Cinnagen, Tehran, Iran), according to the supplier's manual. Concentration and purity of the DNA samples were determined spectrophotometrically (Eppendorf, Germany) by reading A~260~ and A~280~.

DNA amplification by two different targets
------------------------------------------

The B4 and B5 primers ([Table 1](#t01){ref-type="table"}) described previously ([@B06]), were used for detection of *Brucella* genus which encodes a protein of *Brucella abortus* 31 kDa, BCSP31. BCSP31-PCR reaction consisted of 12.5 μL 2× PCR master mixes (Fermentas, USA), 1 μg DNA template, 100 nM of each primers, and nuclease free water up to 25 μL. PCR profile was performed on a thermocycler (iCycler, Bio-Rad, USA) using the following parameters: Denaturation primal at 95 °C for 5 min, 35 cycles of template denaturation at 94 °C for 1 min, 30 s of primer annealing at 64 °C, and 60 s of primer extension at 72 °C with a final extension cycle at 72 °C for 7 min.

###### 

Olignucleotides for detection of *Brucella* used in this study.

  ---------------------------------------------------------------------------------------
  No.   Target                   Olignucleotide sequence              Amplified product
  ----- ------------------------ ------------------------------------ -------------------
  1     BCSP31                   B4: 5′-TGGCTCGGTTGCCAATATCAA-3′\     223 bp
                                 B5: 5 ′-CGCGCTTGCCTTTCAGGTCTG-3      

  2     IS711, *B. abortus*      F: 5′-TGCCGATCACTTAAGGGCCTTCAT-3′\   498 bp
                                 R: 5′-GAC GAACGGAATTTTTCCAATCCC-3′   

  3     IS711, *B. melitensis*   F: 5′-TGCCGATCACTTAAGGGCCTTCAT-3′\   731 bp
                                 R: 5′-AAA TCGCGTCCTTGCTGGTCTGA-3′    
  ---------------------------------------------------------------------------------------

The other primers described previously ([@B08]) specific for *Brucella* spp including, forward primers were derived from insertion sequence 711 (IS711) is unique to identification *of Brucella* species but the reverse primers are different and were derived from *B. abortus* and *B. melitensis* specific locus on chromosomal DNA ([Table 1](#t01){ref-type="table"}). IS711-PCR assay were done in a total volume of 25 μL containing the same mixture were used for BCSP31-PCR.

The amplification programs for *B. abortus* and *B. melitensis* consisted of initial DNA denaturation at 95 °C for 3 min and then cycled 35 times at 95 °C for 90 s, 65 °C for 1 min, and 72 °C for 1 min. We performed a final extension step of 5 min at 72 °C. The reaction products (5 μL) were detected by electrophoresis on 1.5% agarose gel and visualized with UV transilluminator after staining with 2 μg/mL ethidium bromide to determine the size of amplified products.

DNA isolated from *B. melitensis* 16 M provided from Department of Bacterial Vaccines and Antigens Production, Pasteur Institute of Iran and *B. abortus* from the department of biotechnology, faculty of pharmacy, ZUMS, Iran were used as the positive control*.* The negative control strain was *Escherichia coli* ATCC 8739 for determination of specificity assay and to detect the contamination during the extraction stage of the DNA and/or primer. Water was used as negative control. All samples were carried out in duplicate.

Results
=======

Study Patients
--------------

180 suspected patients to brucellosis included in this study. From the total of 128 Wright-positive patients (mean age of 40 years; ranging 15--77 yr), 41 (32%) were female and 87 (67%) were male. Ninety three (72.6%) patients lived in rural areas, 107 (83.6%) had direct contacts with animals or animal products, and 21 (16.4%) acquired their infections by consuming un-pasteurized dairy products.

From 52 Wright-negative serum samples (mean age of 38 years; ranging 10--70 yr), 37 cases (71%) were female and 15 (28%) were male. Thirty six (69.2%) cases had contact with livestock or their products, and 16 (30.8%) had a history of consuming non-pasteurized dairy products.

Testing of serum samples with BCSP31-PCR
----------------------------------------

Detection of *Brucella* genus with B4 and B5 primers are shown in [Figure 1](#f01){ref-type="fig"}. As expected, the *bcsp31* gene amplicon size was 223 bp. Among the 128 Wright positive patients, 123 (96.1%) samples were positive by B4 and B5 primers, and there were only 5 (3.9%) false negative results for Wright-positive samples. A total of 10 out of 52 (19.23%) Wright-negative cases were positive by PCR ([Table 2](#t02){ref-type="table"}).

![Identification of DNA amplified fragments by agarose gel electrophoresis and ethidium bromide staining. An amplicon size of 223 bp was obtained by PCR using Baily's primers (B4, B5) and template DNA from reference *Brucella* spp and patient sera. Lanes: 1, Negative control; 2, 1 kb Ladder; 3, 4, Wright positive sera; 5, 6, *B. abortus* and *B. melitensis;* 7, 8, Wright negative sera; 9, *E. coli.*](bjm-45-533-g001){#f01}

###### 

Table 2. The results of the PCR amplification of the BCSP31 target gene by using B4 and B5 primers.

  Standard tube agglutination (Wright)   Positive       Negative      Total
  -------------------------------------- -------------- ------------- ------------
  Wright \> 1:160                        102 (96.22%)   4 (3.78)      106 (100%)
  Wright \< 1:160                        21 (95.45%)    1 (4.55%)     22 (100%)
  Wright Negative                        10 (19.23%)    42 (80.77%)   52 (100%)
  Total                                  133            47            180

Testing of serum samples with IS711-PCR
---------------------------------------

Detection of *Brucella* spp. in serum samples with *B. abortus* and *B. melitensis* specific primers (IS711) produced amplicons of 498 and 731 bp for *B. abortus* and *B. melitensis*, respectively ([Figures 2](#f02){ref-type="fig"} and [3](#f03){ref-type="fig"}). Amplicons with a molecular size of 498 bp were obtained from 115/180 (63.9%) of serum samples. Of the 115 PCR positive serum samples, 105/115 (91.3%) was obtained from Wright-positive and 10/115 (8.7%) from Wright-negative. However, in the PCR targeting IS711 for detection of *B. melitensis* showed that an amplicon of the 731 bp was obtained, only from 8/128 (6.25%) cases of Wright-positive samples ([Table 3](#t03){ref-type="table"}). Comparison of PCR and serology techniques in the detection of brucellosis is indicated on [Table 4](#t04){ref-type="table"}.

![Identification of DNA amplified fragments by agarose gel electrophoresis and ethidium bromide staining. An amplicon of 498 bp was obtained by PCR using *B. abortus* - specific primers and *Brucella* DNA as template. Lanes: 1, 2, 3, serum DNAs from patients diagnosed with brucellosis; 4, 1 kb Ladder; 5, Positive control for *B. abortus*; 6, *E.coli DNA*; 7, B. melitensis 16 M strain; 8, Negative control.](bjm-45-533-g002){#f02}

![Identification of DNA amplified fragments by agarose gel electrophoresis and ethidium bromide staining. An amplicon size of 731 bp was obtained by PCR using *B. melitensis* - specific primers and *Brucella* DNA as template. Lanes: 1, 1 kb Ladder; 2, Negative control; 3, *E.coli* DNA; 4, *B. abortus; 5*, *6*, serum DNAs from patients diagnosed with brucellosis; 7, Positive control for *B. melitensis* 16 M strain.](bjm-45-533-g003){#f03}

###### 

Table 3. The results of the PCR amplification for *B. abortus* and *B. melitensis*.

  Standard tube agglutination (Wright)   PCR Positive *B. melitensis*   PCR Positive *B. abortus*   PCR Negative   Total
  -------------------------------------- ------------------------------ --------------------------- -------------- ------------
  Wright \> 1:160                        6 (5.66%)                      87 (82.08%)                 13 (12.26%)    106 (100%)
  Wright \< 1:160                        2 (9.1%)                       18 (81.8%)                  2 (9.1%)       22 (100%)
  Wright Negative                        0                              10 (19.23%)                 42 (80.77%)    52 (100%)
  Total                                  8                              115                         57             180

###### 

Comparison of the PCR results with the Wright Method for detection of brucellosis.

  PCR Brucellosis   Wright   Total   
  ----------------- -------- ------- -----
  Positive          113      10      123
  Negative          15       42      57
  Total             128      52      180

Discussion
==========

The diagnosis of brucellosis is challenging as culturing of Brucellae and sero-conversion are time consuming ([@B03]). Therefore, molecular techniques like as PCR are promising alternatives for the diagnosis of infectious diseases caused by fastidious or slowly growth microorganisms such as Brucellae. In this study, we evaluated a PCR assay for detection of *Brucella* spp in human serum samples as templates, and also epidemiology of brucellosis in the Zanjan province of Iran. In the present study, by using of B~4~ and B~5~ primers, 123 out of 128 Wright-positive samples were positive for brucellosis. This observation is in agreement with the suggestions of researchers that SAT titers of less than 1:160 should not be ignored without further follow ups. On the other hand, SAT titers of 1:160 are not indicative of active infection, especially in *Brucella* endemic areas ([@B17]; [@B12]; [@B14]).

Additionally, we compared the sensitivity and specificity of two targets, *bcsp31* and IS711 genes, in PCR in comparison with STA. In the literature, sensitivities and specificities of various PCR assays targeting the *bcsp31* gene to detect *Brucella* DNA in human blood or serum samples have varied from 50% to 100% and 60% to 100%, respectively ([@B22]; [@B19]; [@B02]; [@B01]). Our results indicated 91.6% efficiency for sensitivity of 96% and specificity of 80.7%, using STA as gold standard.

Our results indicate that the species-specific PCR assay with primers IS711 detects higher numbers of *B. abortus* DNA in both Wright-positive and -negative serum samples than *B. melitensis*. These findings are significantly different from PCR results that were reported by [@B16] in Iran and [@B13] in Saudi Arabia, respectively. In these studies, a large number of *B. melitensis* DNA was detected with using the same primers. The sensitivity and specificity of PCR-IS711 compared to STA as gold standard was found to be 88.2% and 80.7%, respectively.

In our study, we used serum samples instead of whole-blood for PCR assay. It has been previously reported that there are fewer inhibitors in the serum than in whole blood, and that the DNA extraction from serum is more efficient compared with whole blood ([@B28]). Despite our satisfactory results, some patients with positive STA showed up as negative by PCR. These false-negatives could be result the presence of either a number of organisms below the detection limit or degradation of target DNA in the serum samples ([@B23]). The fact that the Wright-negative subjects were among the false positive samples could be due to a consistent exposed to the disease agent, examples of who include Veterinarian, Animal husbandry, and housekeeper /farmers. This finding corroborates well with the fact that most infections are found among housekeeper/farmer family and sheep/goats farmers ([@B15]).

In summary, PCR appears to offer several advantages over conventional methods: it is easy to perform; it is rapid; and it is safe for laboratory staffs because the serum based PCR-assay will reduce to risk of handling the microorganism in the laboratory. Therefore, the use of the BCSP, IS711- based PCR assays described here is a promising method for detection of the *Brucella* genus and also identifying *Brucella* spp in clinical samples.
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